{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:14:45Z","timestamp":1765178085480,"version":"3.37.3"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11886-022-01677-6","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T07:02:27Z","timestamp":1645686147000},"page":"567-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-983X","authenticated-orcid":false,"given":"Dennis I.","family":"Narcisse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Katzenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Antonio","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"1677_CR1","first-page":"417","volume":"10","author":"A Swaminathan","year":"2014","unstructured":"Swaminathan A, et al. Lower extremity amputation in peripheral artery disease: Improving patient outcomes. Vasc Health Risk Manag. 2014;10:417\u201324.","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"1677_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","volume":"47","author":"SP Marso","year":"2006","unstructured":"Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1677_CR3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild S, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047\u201353.","journal-title":"Diabetes Care"},{"issue":"11","key":"1677_CR4","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1161\/CIRCRESAHA.115.306884","volume":"118","author":"JA Beckman","year":"2016","unstructured":"Beckman JA, Creager MA. Vascular complications of diabetes. Circ Res. 2016;118(11):1771\u201385.","journal-title":"Circ Res"},{"issue":"6","key":"1677_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","volume":"114","author":"A Goldin","year":"2006","unstructured":"Goldin A, et al. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597\u2013605.","journal-title":"Circulation"},{"issue":"11","key":"1677_CR6","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"G Control","year":"2009","unstructured":"Control G, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288\u201398.","journal-title":"Diabetologia"},{"issue":"6","key":"1677_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jamcollsurg.2018.09.021","volume":"227","author":"MP Goldman","year":"2018","unstructured":"Goldman MP, et al. Effect of intensive glycemic control on risk of lower extremity amputation. J Am Coll Surg. 2018;227(6):596\u2013604.","journal-title":"J Am Coll Surg"},{"issue":"12","key":"1677_CR8","first-page":"e686","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, et al. 2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12):e686\u2013725.","journal-title":"Circulation"},{"issue":"1","key":"1677_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12020-017-1517-9","volume":"61","author":"D Giugliano","year":"2018","unstructured":"Giugliano D, et al. Glycemic control in type 2 diabetes: From medication nonadherence to residual vascular risk. Endocrine. 2018;61(1):23\u20137.","journal-title":"Endocrine"},{"key":"1677_CR10","doi-asserted-by":"crossref","unstructured":"\u2022 American Diabetes Association: 9. Pharmacologic Approaches to glycemic treatment: Standards of medical care in diabetes-2020. Diabetes Care.\u00a02020;43(Suppl 1): p. S98-S110. The American Diabetes Association has recommended expanding the management of T2DM to incorporate therapies with CV risk factor modification, thus highlighting the importance for cardiologists to further understand GLP1 RA and SGLT2i.","DOI":"10.2337\/dc20-S009"},{"issue":"17","key":"1677_CR11","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"},{"issue":"4","key":"1677_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.physbeh.2006.05.048","volume":"89","author":"C Beglinger","year":"2006","unstructured":"Beglinger C, Degen L. Gastrointestinal satiety signals in humans\u2013physiologic roles for GLP-1 and PYY? Physiol Behav. 2006;89(4):460\u20134.","journal-title":"Physiol Behav"},{"issue":"4","key":"1677_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike ZZ, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"1677_CR14","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1677_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"1677_CR16","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"9","key":"1677_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"10193","key":"1677_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"10157","key":"1677_CR19","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"13","key":"1677_CR20","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"key":"1677_CR21","doi-asserted-by":"crossref","unstructured":"Badjatiya A, et al. Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: Results from the EXSCEL Trial. Circ Cardiovasc Interv.\u00a02019;12(12): p. e008018.","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018"},{"key":"1677_CR22","doi-asserted-by":"crossref","unstructured":"Gerstein HC, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med.\u00a02021.","DOI":"10.1056\/NEJMoa2108269"},{"issue":"1","key":"1677_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.amjcard.2018.09.014","volume":"123","author":"JA Gutierrez","year":"2019","unstructured":"Gutierrez JA, et al. Prevalence and outcomes of polyvascular (coronary, peripheral, or cerebrovascular) disease in patients with diabetes mellitus (from the SAVOR-TIMI 53 Trial). Am J Cardiol. 2019;123(1):145\u201352.","journal-title":"Am J Cardiol"},{"issue":"5","key":"1677_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jchf.2014.05.008","volume":"2","author":"DK Gupta","year":"2014","unstructured":"Gupta DK, et al. Heart failure risk across the spectrum of ankle-brachial index: The ARIC study (atherosclerosis risk in communities). JACC Heart Fail. 2014;2(5):447\u201354.","journal-title":"JACC Heart Fail"},{"key":"1677_CR25","doi-asserted-by":"crossref","unstructured":"Chunawala Z, et al. Recurrent admissions for acute decompensated heart failure among patients with and without peripheral artery disease: The ARIC study. J Am Heart Assoc.\u00a02020;9(21): p. e017174.","DOI":"10.1161\/JAHA.120.017174"},{"issue":"4","key":"1677_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2215\/CJN.04411007","volume":"3","author":"YP Liew","year":"2008","unstructured":"Liew YP, et al. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population. Clin J Am Soc Nephrol. 2008;3(4):1084\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1677_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"9","key":"1677_CR28","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","volume":"178","author":"HY Chang","year":"2018","unstructured":"Chang HY, et al. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med. 2018;178(9):1190\u20138.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1677_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"1677_CR30","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","volume":"42","author":"SK Paul","year":"2021","unstructured":"\u2022\u2022 Paul SK, Bhatt DL, Montvida O. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: Real-world study. Eur Heart J. 2021;42(18):1728\u201338. This study provides recent data from a large US patient population demonstrating that patients with T2DM and PAD had increased risk of amputation; however, the large number of patients SGLT2i did not have increased amputation risk. Therefore, there was no suggestion of associated risk of heightened amputation with SGLT2i.","journal-title":"Eur Heart J"},{"issue":"8","key":"1677_CR31","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1007\/s00125-018-4644-9","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: Subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial. Diabetologia. 2018;61(8):1712\u201323.","journal-title":"Diabetologia"},{"issue":"22","key":"1677_CR32","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"1677_CR33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","volume":"142","author":"MP Bonaca","year":"2020","unstructured":"\u2022 Bonaca MP, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58. Circulation. 2020;142(8):734\u201347. Findings from this study show that patients with peripheral artery disease had a greater absolute benefit with reductions in CV death, HF hospitalization, and progression of CKD compared with those without PAD.","journal-title":"Circulation"},{"issue":"21","key":"1677_CR34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"4","key":"1677_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"15","key":"1677_CR36","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"1677_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"1677_CR38","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577\u201385.","journal-title":"Diabetologia"},{"key":"1677_CR39","doi-asserted-by":"crossref","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet.\u00a01998;352(9131): p. 854\u201365.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"issue":"15","key":"1677_CR40","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"6","key":"1677_CR41","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","volume":"169","author":"A Kooy","year":"2009","unstructured":"Kooy A, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616\u201325.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1677_CR42","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2337\/dc12-0719","volume":"36","author":"J Hong","year":"2013","unstructured":"Hong J, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304\u201311.","journal-title":"Diabetes Care"},{"issue":"6","key":"1677_CR43","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2337\/dc14-2868","volume":"38","author":"LA Leiter","year":"2015","unstructured":"Leiter LA, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38(6):1145\u201353.","journal-title":"Diabetes Care"},{"issue":"2","key":"1677_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s13300-011-0002-3","volume":"2","author":"C Koliaki","year":"2011","unstructured":"Koliaki C, Doupis J. Incretin-based therapy: A powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011;2(2):101\u201321.","journal-title":"Diabetes Ther"},{"issue":"14","key":"1677_CR45","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"18","key":"1677_CR46","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, et al. Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579\u201388.","journal-title":"Circulation"},{"issue":"14","key":"1677_CR47","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"9982","key":"1677_CR48","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067\u201376.","journal-title":"Lancet"},{"issue":"3","key":"1677_CR49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"1677_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"12","key":"1677_CR51","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155\u201366.","journal-title":"JAMA"},{"issue":"7","key":"1677_CR52","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.numecd.2014.01.017","volume":"24","author":"M Monami","year":"2014","unstructured":"Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689\u201397.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"1677_CR53","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","volume":"134","author":"RL Page 2nd","year":"2016","unstructured":"Page RL 2nd, et al. Drugs that may cause or exacerbate heart failure: A scientific statement from the American Heart Association. Circulation. 2016;134(6):e32-69.","journal-title":"Circulation"},{"issue":"8","key":"1677_CR54","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/archinte.1997.00440290014001","volume":"157","author":"R Bressler","year":"1997","unstructured":"Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157(8):836\u201348.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1677_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/dom.12821","volume":"19","author":"S Bain","year":"2017","unstructured":"Bain S, et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab. 2017;19(3):329\u201335.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1677_CR56","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMra041001","volume":"351","author":"H Yki-Jarvinen","year":"2004","unstructured":"Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106\u201318.","journal-title":"N Engl J Med"},{"issue":"24","key":"1677_CR57","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457\u201371.","journal-title":"N Engl J Med"},{"issue":"14","key":"1677_CR58","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","volume":"170","author":"SE Nissen","year":"2010","unstructured":"Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191\u2013201.","journal-title":"Arch Intern Med"},{"issue":"10","key":"1677_CR59","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","volume":"298","author":"S Singh","year":"2007","unstructured":"Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189\u201395.","journal-title":"JAMA"},{"issue":"8","key":"1677_CR60","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/pds.1615","volume":"17","author":"A Cobitz","year":"2008","unstructured":"Cobitz A, et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiol Drug Saf. 2008;17(8):769\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9681","key":"1677_CR61","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125\u201335.","journal-title":"Lancet"},{"issue":"9493","key":"1677_CR62","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279\u201389.","journal-title":"Lancet"},{"key":"1677_CR63","unstructured":"Vaccaro O, et al.\u00a0Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol.\u00a02017;5(11): p. 887\u2013897."},{"issue":"1","key":"1677_CR64","doi-asserted-by":"publisher","first-page":"15781","DOI":"10.1038\/s41598-020-72967-8","volume":"10","author":"B Sinha","year":"2020","unstructured":"Sinha B, Ghosal S. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: A meta-analysis of its risks and benefits from prospective trials. Sci Rep. 2020;10(1):15781.","journal-title":"Sci Rep"},{"key":"1677_CR65","doi-asserted-by":"crossref","unstructured":"Rados DV, et al.\u00a0All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis. Diabetes Res Clin Pract.\u00a02021;173:p. 108688.","DOI":"10.1016\/j.diabres.2021.108688"},{"issue":"3","key":"1677_CR66","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/2048872617719639","volume":"8","author":"V Bataille","year":"2019","unstructured":"Bataille V, et al. Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: Data from the FAST-MI 2005 registry. Eur Heart J Acute Cardiovasc Care. 2019;8(3):218\u201330.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"8","key":"1677_CR67","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2213-8587(14)70088-9","volume":"2","author":"V Ritsinger","year":"2014","unstructured":"Ritsinger V, et al. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised diabetes mellitus insulin glucose infusion in acute myocardial infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol. 2014;2(8):627\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1677_CR68","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"1677_CR69","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"26","key":"1677_CR70","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/eurheartj\/ehaa777","volume":"42","author":"G Ferrannini","year":"2021","unstructured":"Ferrannini G, et al. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J. 2021;42(26):2565\u201373.","journal-title":"Eur Heart J"},{"issue":"24","key":"1677_CR71","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-022-01677-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-022-01677-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-022-01677-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T14:20:36Z","timestamp":1651674036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-022-01677-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1677"],"URL":"https:\/\/doi.org\/10.1007\/s11886-022-01677-6","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"type":"print","value":"1523-3782"},{"type":"electronic","value":"1534-3170"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"12 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"J.A.G discloses the following relationships: Consulting: Amgen Inc., Janssen Pharmaceuticals, and Medicure Inc; Research: Veterans Health Administration. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}